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LETTER TO THE EDITOR

Levosulpiride-induced Hyperprolactinemia
Sir,

Dyspepsia is a common concern of patients in both the hospital
and outpatient settings. For symptomatic treatment of this,
there are many over-the-counter drugs available in our country.
Levosulpiride is commonly used for dyspepsia, since this
became available as a new prokinetic agent in Pakistan without a
prescription.
Previously, prokinetic agents like domperidone and metoclopramide have been reported to cause hyperprolactinemia as one
of their unavoidable side eﬀects by blocking central D2
dopamine receptors at the hypothalamus and anterior pituitary
1
level. However, this side eﬀect of these old drugs in causing
hyperprolactinema was moderate, usually in the range of <100
ng/mL. Recently, a few cases have been reported with levosulpiride, causing increased serum prolactin in the range of >200
ng/mL.2
Here, we present two patients who were diagnosed with levosulpiride-induced hyperprolactinemia with their prolactin level
normaliSing with discontinuation of this drug. The ﬁrst patient
was a 40- year woman referred to Endocrinology Unit for the evaluation of galactorrhoea. Her serum prolactin was reported as
49.40 ng/mL (normal range: 4-18.5 ng/mL). The second patient
was a 28-year woman who presented with a history of irregular
periods for a few months, serum prolactin checked by her
primary physician was 109.5 ng/mL, who then referred her to
Endocrinology Unit for further workup and management.
On detailed history taking, both admitted that they had been
experiencing acid peptic symptoms and were taking Levosulpiride tablets of 25 mg and 50 mg, two to three times per day,
respectively for the last 3-4 months prior to their presentation.
They were advised to stop this agent and follow-up in the clinic
after 1 month with repeat serum prolactin level. After one month,
both reported improvement in their initial symptoms and repeat
prolactin levels were 24 ng/mL and 40.40 ng/mL, respectively.
Levosulpiride acts via antagonising central D2 dopamine recep-
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tors and show its therapeutics as well as adverse eﬀects like
hyperprolactinemia by that mechanism.
Data regarding levosulpiride-induced hyperprolactinemia is
scarce. Lozano et al. in his prospective study of 342 participants
has reported galactorrhoea in 26.7% patients on levosulpiride.3
Our intent in sending this communication is to help create awareness amongst health professionals regarding the association
between levosulpiride and raised serum prolactin levels. In the
management process, the ﬁrst step should be to discontinue levosulpiride, repeat prolactin level in a few weeks; and if prolactin
levels normalise, then avoid unnecessary costly workup.
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